Rosalie E. Ferner
Department of Neurology
Guy's Hospital
St Thomas' St
London SE1 9RT
UK
Name/email consistency: high
- [18F]2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET) as a diagnostic tool for neurofibromatosis 1 (NF1) associated malignant peripheral nerve sheath tumours (MPNSTs): a long-term clinical study. Ferner, R.E., Golding, J.F., Smith, M., Calonje, E., Jan, W., Sanjayanathan, V., O'Doherty, M. Ann. Oncol. (2008)
- Guidelines for the diagnosis and management of individuals with neurofibromatosis 1. Ferner, R.E., Huson, S.M., Thomas, N., Moss, C., Willshaw, H., Evans, D.G., Upadhyaya, M., Towers, R., Gleeson, M., Steiger, C., Kirby, A. J. Med. Genet. (2007)
- Neurofibromatosis 1 and neurofibromatosis 2: a twenty first century perspective. Ferner, R.E. Lancet. Neurol (2007)
- Neurofibromatosis 1. Ferner, R.E. Eur. J. Hum. Genet. (2007)
- Neurofibromatous neuropathy in neurofibromatosis 1 (NF1). Ferner, R.E., Hughes, R.A., Hall, S.M., Upadhyaya, M., Johnson, M.R. J. Med. Genet. (2004)
- International consensus statement on malignant peripheral nerve sheath tumors in neurofibromatosis. Ferner, R.E., Gutmann, D.H. Cancer Res. (2002)
- Neurofibroma and schwannoma. Ferner, R.E., O'Doherty, M.J. Curr. Opin. Neurol. (2002)









